Close menu

February 7th, 2024 | 07:30 CET

BASF shares on the upswing, BioNTech sees breakthrough in cancer, and Defence Therapeutics benefits from study

  • Biotechnology
  • chemicals
  • Cancer
Photo credits: BASF SE

Can BASF shareholders look forward to better times? One analyst is certainly hopeful. He believes that the chemical industry will recover in 2024. However, the price target gives pause for thought. The development of cervical cancer is also concerning. According to a new study, the number of cases has risen sharply in recent years, and with it, HPV infections. Accordingly, more HPV vaccines are urgently needed. The market volume is expected to more than double to over USD 15 billion in just a few years. Defence Therapeutics aims to become a profiteer. The biotech company is fighting cancer with its Accum™ platform. BioNTech CEO Ugur Sahin also believes that humanity will get cancer under control, thanks in part to artificial intelligence. The Company is currently working on 30 cancer therapies. Is it a good time to invest now?

time to read: 3 minutes | Author: Fabian Lorenz

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    Defence Therapeutics: Study reveals potential in the billion-dollar market

    The market for HPV vaccines is expected to grow from USD 6.51 billion in 2022 to USD 15.94 billion by 2028, representing a doubling within just a few years. This conclusion is drawn from a recent study by Stratview Research. Background: Human Papillomaviruses (HPV) are among the most common viruses transmitted through intimate contact. They often result in cancers such as genital and cervical cancer. According to the study, the COVID-19 pandemic has had a significant impact on the spread of HPV. The overwhelmed healthcare systems led to significantly fewer screenings for sexually transmitted diseases. As a result, there are considerably more cases and fatalities, particularly in cervical cancer.

    Defence Therapeutics should benefit from the increasing demand for HPV vaccines. The Canadian biotech company has developed a versatile platform technology, Accum™. The unconjugated Accum™ molecule can be used to fight cancer in two ways. Firstly, by directly inducing cell death in various cancer cell lines (T-cell lymphoma, colon cancer, melanoma and breast cancer). It also works indirectly by "alerting" the affected person's immune system to fight the cancer cells. As a result, cancer and other infectious diseases can be fought efficiently and very effectively. Research into various cancer vaccines is already underway. Defence Therapeutics is currently valued at less than CAD 100 million.

    BioNTech: Defeating cancer with the help of AI

    BioNTech currently has a market capitalization of around USD 22 billion. The share price is currently testing support at around USD 90. Due to declining income from the COVID-19 vaccine and potential revenues from new drugs only in the medium term, the German biotech star is running out of steam. However, CEO Ugur Sahin is confident about the Company's future prospects. In an interview with "Der Spiegel", Sahin sees the field of medicine as well on the way to "controlling or ideally curing cancer in the long term". The BioNTech co-founder believes that digital technologies and artificial intelligence are driving research forward. He, therefore, sees "no fundamental reason why many types of cancer should not be detectable earlier and more effectively treatable." BioNTech itself has already invested in AI specialists in the past. Sahin believes that by 2026, the first drugs should be ready for approval. By 2030, BioNTech should then have an extensive portfolio of cancer therapies. The Company currently has a research pipeline comprising 30 new cancer therapies.

    BASF: Price target raises questions

    For almost two years, BASF's stock has been fluctuating – with a few deviations upward and downward – between EUR 50 and EUR 40. Currently, it is trading at just under EUR 45. The economic sensitivity of the chemical industry has provided little upside potential. However, there are increasing signs that the downturn in the sector is coming to an end. Berenberg has recently expressed a positive outlook. Those who had bet on the upturn in the chemical industry in 2023 should be rewarded in the current year. Volumes and margins are expected to develop positively in 2024. Diversified companies, in particular, should be able to benefit from this. It all sounds positive for BASF and like a "Buy" recommendation. However, analysts cannot bring themselves to that conclusion. For them, BASF shares with a price target of EUR 46 are only a "Hold".

    BASF is currently making negative headlines in another aspect. According to reports from ZDF magazine "frontal" and "Der Spiegel", the chemical company is increasingly involved in the system of oppression against the Uyghur minority in China. According to the report, employees of a joint venture between BASF and a Chinese company made home visits to Uyghur families in 2018/19, conducted investigations, and apparently passed on their findings to state authorities. In some cases, it was reported that the employees even moved in with the families. BASF intends to investigate the allegations.

    The fight against and cure for cancer represents a billion-dollar market - and the trend is still rising. Defence Therapeutics has developed an exciting platform and is building a research pipeline. The valuation is not high, and there are frequent takeover speculations. The Canadians would certainly also be a good fit for BioNTech. The German biotech company not only has a full pipeline but also cash for possible further acquisitions. At BASF there is the lure of a generous dividend, but operationally, there has been little reason for joy in recent years.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Juliane Zielonka on February 22nd, 2024 | 07:00 CET

    Royal Helium, Fresenius, BASF: Chemical and Healthcare industry - Where is the next investment opportunity?

    • Helium
    • Healthcare
    • chemicals

    Europe is in the midst of an industrial upheaval due to the Green Deal, which presents both challenges and opportunities for investors. While companies like BASF are arguing for deregulation and increased subsidies to support the green transition, healthcare company Fresenius is undergoing a period of radical change and realignment. The medical technology market is booming. The global MedTech market size amounted to USD 574,002.45 million in 2022 and is expected to increase to USD 814,159.2 million by 2028, with an annual growth rate of 6.0%. Critical raw materials such as helium are in particularly high demand. Royal Helium is one of the producers of this valuable gas and impresses with a well thought-out and sustainable business model. Where does the next investment opportunity lie?


    Commented by Fabian Lorenz on February 21st, 2024 | 07:00 CET

    Top news: BYD, Bayer and Globex Mining

    • Mining
    • Gold
    • Commodities
    • Electromobility
    • chemicals

    Bayer shocked investors yesterday with the announcement of its dividend cut, which shouldn't have been much of a surprise. The Company is burdened with high debt, endless legal fines, and an empty pharmaceutical pipeline. In an initial reaction, analysts have lowered the share price target. BYD, on the other hand, is doing well operationally. Only the share price is not picking up. Will a share buyback turn the share price around? For those who want to profit from the commodity boom with reduced risk, then Globex Mining's stock is attractive. The news flow is strong, and those who act quickly can still register and follow the live presentation of the mining incubator at the 10th International Investment Forum, IIF, today.


    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.